Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Israeli ADHD-Drug Maker Alcobra Seeks $27 Million in IPO

Alcobra Pharma, an Israeli company developing an oral medicine with reduced side effects to treat attention deficit hyperactivity disorder, filed to raise as much as $27.3 million in a Nasdaq initial public offering.

Alcobra plans to sell 2.27 million shares in a price range of $10 to $12 a share to fund work on the drug, according to a filing on the U.S. Securities and Exchange Commission website. Aegis Capital Corp. was hired as sole bookrunner while Sunrise Securities Corp. is co-manager.

ADHD affects 3 percent to 5 percent of school-age children, mostly boys, according to the National Institutes of Health. Alcobra said that, in contrast to most current amphetamine medications with “significant” side effects, the Tel Aviv-based drugmaker’s MG01CI treatment showed no detectable changes in appetite, sleep patterns or mood in a mid-stage clinical study in 120 adults.

The market for pharmaceutical treatments for ADHD in 2012 is estimated to exceed $3.8 billion in the U.S., Alcobra said. The company plans to use the proceeds of the stock sale to finance two advanced-stage trials in the U.S. estimated to cost $6 million each, it said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.